Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kairos Pharma, LTD.KAPA · Entity 8244 | Director | September 16, 2025 | December 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kairos Pharma, LTD.
Report date September 16, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 54,286 |
Reported balance
After 2025-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-16 · Grant · Acquired 10,000 · Balance 54,286 F1: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO. F2: Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 73,370 |
Reported balance
After 2025-10-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-10-08 · Grant · Acquired 19,084 · Balance 73,370 F3: Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4: Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO.
F2: Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.
F3: Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F4: Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Dec 23, 2025 06:03 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028895 · ownership.xml · nonDerivative · entry 2 Bae Hyun W. · CIK 0001988551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,370 F3 · shares: Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4 · balance_after: Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting. Read SEC document |
| September 16, 2025 Filed Dec 23, 2025 06:03 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028895 · ownership.xml · nonDerivative · entry 1 Bae Hyun W. · CIK 0001988551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,286 F1 · shares: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO. F2 · balance_after: Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.